-
Post date
July 4, 2021
-
Posted by
Lukas Kane
-
Posted in
Biotech, Breakthrough Therapy, Bucillamine, CBD research and development, clinical testing, Fast Track, FDA approval, Featured Content, Health Science, ischemia-reperfusion injury, Kane, Mushroom Moves, Mushrooms, Orphan Drug, preclinical testing, preclinical trials, psilcoybin, Psychedelics, Rare Pediatric Disease, research and development, Revive Therapeutics, RVV.C, Scribes, Series, UCSF, University of California
-
Post date
April 27, 2021
-
Posted by
Lukas Kane
-
Posted in
5 best Canadian Biotechs, Biotech, Biotech collaborations, Bucillamine, Canadian Biotech, cancer treatment, Cannabis, clinical sites, Covid-19 treatment, CRO, CymaBay Therapeutics (CBAY.NASDAQ), Fabio Chianelli, Featured Content, Health Science, Institutional Review Board, Investigational new drug, IRB, Kane, liver disease, massive buying, mushroom, mushroom research, Mushrooms, Novotech, Pharm-Olam LLC, PharmaTher, PharmaTher (PHRM.C), Phase 3 FDA trial, Phase 3 trial, Psychedelics, research, resperitory viral infections, Revive Therapeutics, RVV.C, Scribes, Series, shrooms, stock price surge, undervalued bio tech companies, wealth creation
